About: TRAIL receptor upregulation and the implication of KRAS/BRAF mutations in human colon cancer tumours

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: TRAIL receptor upregulation and the implication of KRAS/BRAF mutations in human colon cancer tumours Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	TRAIL raises hopes as a promising anti-tumor agent due to its selectivity toward cancer cells. Since TRAIL receptor availability can be analogous to ligand efficacy, we performed RT-PCR and immunohistochemical analysis of DR4 and DR5 in 51 colon cancer biopsy specimens and respective normal mucosa. The results showed that DR4 and DR5 were significantly upregulated in 37 and 47% of the tumor samples respectively, while both DR4 and DR5 were co-instantaneously upregulated in 31% of the samples analyzed. Positive transcriptional regulation of DRs was recorded as early as Dukes' A stage. Possible contribution of frequent oncogenic mutations in the MAPK pathway was investigated by direct sequencing in all 51 tumors. Samples (6/8) hosting either a KRAS(G12V) or BRAF(V600E) mutation, significantly amplified the upregulated expression of DR4 and DR5, showing strong inter-relation between overexpression and presence of oncogenic KRAS/ BRAF mutations and DRs expression. TRAIL raises hopes as a promising anti-tumor agent due to its selectivity toward cancer cells. Since TRAIL receptor availability can be analogous to ligand efficacy, we performed RT-PCR and immunohistochemical analysis of DR4 and DR5 in 51 colon cancer biopsy specimens and respective normal mucosa. The results showed that DR4 and DR5 were significantly upregulated in 37 and 47% of the tumor samples respectively, while both DR4 and DR5 were co-instantaneously upregulated in 31% of the samples analyzed. Positive transcriptional regulation of DRs was recorded as early as Dukes' A stage. Possible contribution of frequent oncogenic mutations in the MAPK pathway was investigated by direct sequencing in all 51 tumors. Samples (6/8) hosting either a KRAS(G12V) or BRAF(V600E) mutation, significantly amplified the upregulated expression of DR4 and DR5, showing strong inter-relation between overexpression and presence of oncogenic KRAS/ BRAF mutations and DRs expression. (en)
Title	TRAIL receptor upregulation and the implication of KRAS/BRAF mutations in human colon cancer tumours TRAIL receptor upregulation and the implication of KRAS/BRAF mutations in human colon cancer tumours (en)
skos:prefLabel	TRAIL receptor upregulation and the implication of KRAS/BRAF mutations in human colon cancer tumours TRAIL receptor upregulation and the implication of KRAS/BRAF mutations in human colon cancer tumours (en)
skos:notation	RIV/68378050:_____/09:00334035!RIV10-MSM-68378050
http://linked.open...avai/riv/aktivita	P Z
http://linked.open...avai/riv/aktivity	P(1M0506), Z(AV0Z50520514)
http://linked.open...iv/cisloPeriodika	9
http://linked.open...vai/riv/dodaniDat	2010
http://linked.open...aciTvurceVysledku	Anděra, Ladislav
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Ústav molekulární genetiky AV ČR, v. v. i.
http://linked.open...dnocenehoVysledku	346655
http://linked.open...ai/riv/idVysledku	RIV/68378050:_____/09:00334035
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	colorectal tumours; TRAIL receptors expression; KRAS/ BRAF oncogenic mutations (en)
http://linked.open.../riv/klicoveSlovo	KRAS/ BRAF oncogenic mutations TRAIL receptors expression colorectal tumours
http://linked.open...odStatuVydavatele	DE - Spolková republika Německo
http://linked.open...ontrolniKodProRIV	[E750F8202303]
http://linked.open...i/riv/nazevZdroje	International Journal of Cancer
http://linked.open...in/vavai/riv/obor	EB
http://linked.open...ichTvurcuVysledku	1 (xsd:int)
http://linked.open...cetTvurcuVysledku	9 (xsd:int)
http://linked.open...vavai/riv/projekt	Center of Molecular and Cellular Immunology
http://linked.open...UplatneniVysledku	2009
http://linked.open...v/svazekPeriodika	125
http://linked.open...iv/tvurceVysledku	Anděra, Ladislav Oikonomou, E. Pintzas, A. Katseli, A. Kontogeorgos, G. Kosmidou, V. Kothonidis, K. Mourtzoukou, D. Zografos, G.
http://linked.open...ain/vavai/riv/wos	000270750000016
http://linked.open...n/vavai/riv/zamer	Molekulárně genetické a buněčné základy klíčových biologických procesů: genová exprese, onkogeneze, replikace virů, imunita a vývoj organismů
issn	0020-7136
number of pages	9 (xsd:int)

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 49 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software